Regarding the addition of liraglutide to other medical treatments, a recent retrospective analysis of electronic health records assessed the effects of liraglutide and dapagliflozin (SGLT2 inhibitor) on body weight and glycemic control in people with T1DM over 12 months. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.